Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Métodos Terapêuticos e Terapias MTCI
Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Ann Thorac Cardiovasc Surg ; 28(3): 204-213, 2022 Jun 20.
Artigo em Inglês | MEDLINE | ID: mdl-34937821

RESUMO

PURPOSE: High-dose heparin has been suggested to reduce consumption coagulopathy. MATERIALS AND METHODS: In a randomized, blinded, prospective trial of patients undergoing elective, complex cardiac surgery with cardiopulmonary bypass, patients were randomized to one of three groups: 1) high-dose heparin (HH) receiving an initial heparin dose of 450 u/kg, 2) heparin concentration monitoring (HC) with Hepcon Hemostasis Management System (HMS; Medtronic, Minneapolis, MN, USA) monitoring, or 3) a control group (C) receiving a standard heparin dose of 300 u/kg. Primary outcome measures were blood loss and transfusion requirements. RESULTS: There were 269 patients block randomized based on primary versus redo sternotomy to one of the three groups from August 2001 to August 2003. There was no difference in operative bleeding between the groups. Chest tube drainage did not differ between treatment groups at 8 hours (median [25th percentile, 75th percentile] for control group was 321 [211, 490] compared to 340 [210, 443] and 327 [250, 545], p = 0.998 and p = 0.540, for HH and HC treatment groups, respectively). The percentage of patients receiving transfusion was not different among the groups. CONCLUSION: Higher heparin dosing accomplished by either activated clot time or HC monitoring did not reduce 24-hour intensive care unit blood loss or transfusion requirements.


Assuntos
Procedimentos Cirúrgicos Cardíacos , Heparina , Anticoagulantes , Procedimentos Cirúrgicos Cardíacos/efeitos adversos , Ponte Cardiopulmonar/efeitos adversos , Heparina/efeitos adversos , Humanos , Preparações de Plantas , Estudos Prospectivos , Resultado do Tratamento , Tempo de Coagulação do Sangue Total
2.
J Cardiothorac Vasc Anesth ; 33(5): 1393-1406, 2019 May.
Artigo em Inglês | MEDLINE | ID: mdl-30201404

RESUMO

Disorders affecting red blood cells (RBCs) are uncommon yet have many important physiologic considerations for patients undergoing cardiac surgery. RBC disorders can be categorized by those that are congenital or acquired, and further by disorders affecting the RBC membrane, hemoglobin, intracellular enzymes, or excessive RBC production. A foundational understanding of the physiologic derangement for these disorders is critical when considering perioperative implications and optimization, strategies for cardiopulmonary bypass, and the rapid recognition and treatment if complications occur. This review systematically outlines the RBC disorders of frequency and relevance with an emphasis on how the disorder affects normal physiologic processes, a review of the literature related to the disorder, and the implications and recommendations for patients undergoing cardiac surgery.


Assuntos
Procedimentos Cirúrgicos Cardíacos/métodos , Eritrócitos/fisiologia , Doenças Hematológicas/sangue , Doenças Hematológicas/diagnóstico , Assistência Perioperatória/métodos , Transfusão de Sangue Autóloga/métodos , Procedimentos Cirúrgicos Cardíacos/efeitos adversos , Eritrócitos Anormais/fisiologia , Doenças Hematológicas/cirurgia , Humanos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA